Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was founded in 2015 and is based in Incheon, South Korea.
Metrics to compare | 310210 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship310210PeersSector | |
---|---|---|---|---|
P/E Ratio | −51.9x | −10.1x | −0.5x | |
PEG Ratio | 18.41 | −0.02 | 0.00 | |
Price/Book | 39.3x | 3.0x | 2.6x | |
Price / LTM Sales | - | 36.2x | 3.3x | |
Upside (Analyst Target) | 85.5% | 18.7% | 42.8% | |
Fair Value Upside | Unlock | 1.3% | 6.5% | Unlock |